Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
The results of linear regression analysis between miR-126 or miR-223 and baseline clinical and laboratory parameters are presented in Table 2.Association of miR-223 and miR-126 with clinical and laboratory parameters (Spearman’s rank correlation coefficient, ρ).ParametersmiR-223miR-126ρpρpAge (n = 628)−0.21 p < 0.0001 −0.28 p < 0.0001 Sex (ref:female) (n = 628)0.15 p = 0.0001 0.01p = 0.78Hypertension (n = 627)−0.05p = 0.19−0.18 p < 0.0001 MAP (n = 627)−0.02p = 0.60−0.02p = 0.66BMI (n = 625)−0.10 p = 0.009 −0.13 p = 0.0008 Diabetes (n = 628)−0.08 p = 0.04 −0.09 p = 0.03 CRP (n = 591)−0.03p = 0.43−0.04p = 0.28Serum Creatinine (n = 562)−0.31 p < 0.0001 −0.23 p < 0.0001 eGFR (n = 562)0.30 p < 0.0001 0.26 p < 0.0001 Urea (n = 549)−0.29 p < 0.0001 −0.25 p < 0.0001 Calcium (n = 552)0.09 p = 0.03 −0.02p = 0.68Phosphate (n = 548)−0.09 p = 0.04 −0.17 p < 0.0001 PTH (n = 438)−0.26 p < 0.0001 −0.23 p < 0.0001 25-OH-D (n = 330)−0.08p = 0.17−0.09p = 0.12Proteinuria (n = 524)−0.07p = 0.19−0.10 p = 0.02 Hemoglobin (n = 583)0.29 p < 0.0001 0.24 p < 0.0001 Leukocyte count (n = 581)0.31 p < 0.0001 0.04p = 0.28Platelet count (n = 580)0.24 p < 0.0001 0.18 p < 0.0001 Glucose (n = 537)−0.04p = 0.31−0.08p = 0.08Triglycerides (n = 518)−0.03p = 0.440.01p = 0.91Cholesterol (n = 527)0.16 p = 0.0002 0.14 p = 0.0009 HDL (n = 440)0.08p = 0.110.06p = 0.22LDL (n = 422)0.15p = 0.0020.13p = 0.006MAP: mean arterial pressure; BMI: body mass index; CRP: C-reactive protein; eGFR: estimated glomerular filtration rate; PTH: parathyroid hormone; 25-OH-D: 25-hydroxy vitamin D; HDL: high-density lipoprotein; LDL: low-density lipoprotein.The healthy control group was excluded from the analysis of laboratory characteristics and the RRT group was excluded for non-interpretable laboratory parameters (serum calcium, phosphate, urea, eGFR and proteinuria), due to the dialysis.
Source: Association of miR-126 and miR-223 with clinical and laboratory parameters. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients
Study design awaiting verification · Scientific Reports · 2019
Original publication title
Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients
© The Author(s) 2019
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Several microRNAs (miRNAs) have been linked to chronic kidney disease (CKD) mortality, cardiovascular (CV) complications and kidney disease progression. However, their association with clinical outcomes remains poorly evaluated. We used real-time qPCR to measure serum levels of miR-126 and miR-223 in a large cohort of 601 CKD patients (CKD stage G1 to G5 patients or on renal replacement therapy: CKD G5D) from Ghent University Hospital and 31 healthy controls. All-cause mortality and cardiovascular and renal events were registered as endpoints over a 6 year follow-up period. miR-126 levels were significantly lower from CKD stage G2 on, compared to controls.
The serum levels of miR-223 were significantly lower from CKD stage G3B on. When considering overall mortality, patients with levels of either miR-126 or miR-223 below the median had a lower survival rate. Similar results were observed for CV and renal events. The observed link between the two miRNAs’ seric levels and mortality, cardiovascular events or renal events in CKD appears to depend on eGFR. However, this does not preclude their potential role in the pathophysiology of CKD. In conclusion, CKD is associated with a decrease in circulating miR-223 and miR-126 levels.
Authors’ abstract
Several microRNAs (miRNAs) have been linked to chronic kidney disease (CKD) mortality, cardiovascular (CV) complications and kidney disease progression. However, their association with clinical outcomes remains poorly evaluated. We used real-time qPCR to measure serum levels of miR-126 and miR-223 in a large cohort of 601 CKD patients (CKD stage G1 to G5 patients or on renal replacement therapy: CKD G5D) from Ghent University Hospital and 31 healthy controls. All-cause mortality and cardiovascular and renal events were registered as endpoints over a 6 year follow-up period. miR-126 levels were significantly lower from CKD stage G2 on, compared to controls.
The serum levels of miR-223 were significantly lower from CKD stage G3B on. When considering overall mortality, patients with levels of either miR-126 or miR-223 below the median had a lower survival rate. Similar results were observed for CV and renal events. The observed link between the two miRNAs’ seric levels and mortality, cardiovascular events or renal events in CKD appears to depend on eGFR. However, this does not preclude their potential role in the pathophysiology of CKD. In conclusion, CKD is associated with a decrease in circulating miR-223 and miR-126 levels.
Publication and source details
Original title: Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients
Ophélie Fourdinier; Eva Schepers; Valérie Metzinger-Le Meuth; Griet Glorieux; Sophie Liabeuf; Francis Verbeke; Raymond Vanholder; Benjamin Brigant; Anneleen Pletinck; Momar Diouf; Stéphane Burtey; Gabriel Choukroun; Ziad A. Massy; Laurent Metzinger; on behalf of the European Uremic Toxin Work Group-EUToxArgilesAngel10BeigeJoachim11BrunetPhilippe7CohenGerald12DeifOmar Abou13EvenepoelPieter14FliserDanilo15FridolinIvo16GmerekAndreas17JankowskiJoachim18JankowskiVera18MasereeuwRoos19MischakHarald20OrtizAlberto21PernaAlessandra22Rodriguez-PortilloJuan Mariano23SchanstraJoost24SpasovskiGoce25StamatialisDimitrios26SteppanSonja27StorrMarkus28StegmayrBernd G.29StenvinkelPeter30ThornalleyPaul J.31WiecekAndrej32
Scientific Reports · 2019
© The Author(s) 2019https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.https://doi.org/10.13039/100000042Amgen Foundation (Amgen Foundation, Inc.)https://doi.org/10.13039/100004702Baxter International (Baxter International Inc.)https://doi.org/10.13039/501100003042Else Kr&#x00F6;ner-Fresenius-Stiftung (Else Kroner-Fresenius Foundation)https://doi.org/10.13039/100004330GlaxoSmithKline (GlaxoSmithKline plc.)https://doi.org/10.13039/100001238Merck Company Foundationhttps://doi.org/10.13039/100004329Genzyme (Genzyme Corporation)Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T18:42:37.352330+00:00
DOI: 10.1038/s41598-019-41101-8 · PMC6418179